Kolon TissueGene, Inc. (KOSDAQ:950160)
South Korea
· Delayed Price · Currency is KRW 80,000
-2,100 (-2.56%)
At close: Dec 5, 2025
Kolon TissueGene Revenue
Kolon TissueGene had revenue of 1.72B KRW in the quarter ending September 30, 2025, a decrease of -18.23%. This brings the company's revenue in the last twelve months to 5.08B, up 0.20% year-over-year. In the year 2024, Kolon TissueGene had annual revenue of 5.07B with 36.90% growth.
Revenue (ttm)
5.08B
Revenue Growth
+0.20%
P/S Ratio
1,311.37
Revenue / Employee
175.07M
Employees
29
Market Cap
6,657.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.07B | 1.37B | 36.90% |
| Dec 31, 2023 | 3.71B | -5.75B | -60.81% |
| Dec 31, 2022 | 9.46B | 5.45B | 136.22% |
| Dec 31, 2021 | 4.00B | 447.31M | 12.58% |
| Dec 31, 2020 | 3.56B | 521.01M | 17.17% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |